Skip to main content

Table 2 Adverse reactions resulting in discontinuation of cART, n (%)

From: Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults

Patients with ≥ 1 adverse reaction

23

Total number of adverse reactions

28

Types of adverse reaction

 

 Dermatological

12 (42.9)

 Gastrointestinal/hepatic

2 (7.1)

 Neuropsychiatric

13 (46.4)

 Endocrine/metabolic

1 (3.6)

Severity of adverse reaction

 

 Mild (symptoms do not require major medical intervention)

25 (89.3)

 Moderate (requires medical treatment or hospitalisation)

3 (10.7)

 Severe (fatal or life threatening)

0 (0)